Nonadherence to antipsychotic treatment in patients with schizophrenic disorders

Neuroendocrinology Letters

Volumn 28, Issue SUPPL. 1, 2007, Pages 95-116

  Švestka, Jaromir ^a   Bitter, Istvan ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Antipsychotics; Schizophrenic disorder; Treatment adherence

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RIBOFLAVIN; RISPERIDONE;

AKATHISIA; ARTICLE; CLINICAL ASSESSMENT; COGNITIVE THERAPY; DISEASE EXACERBATION; DOCTOR PATIENT RELATION; DOSAGE SCHEDULE COMPARISON; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; HOSPITALIZATION; HUMAN; MOTIVATION; OBESITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROGNOSIS; PSYCHOEDUCATION; QUESTIONNAIRE; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDAL BEHAVIOR; UNSPECIFIED SIDE EFFECT; VIOLENCE; WEIGHT GAIN;

EID: 34047199256     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. Adams SG, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis. 1993; 181: 558-560.
2. Ascher-Svanum H, Nyhuis AW, Tunis SL et al. Time to all-cause discontinuation following randomization to open-label olanzapine, risperidone, or conventional antipsychotic treatment for schizophrenia (Abstract). Biol Psychiatry 2005; 57 (Suppl.): 445.
3. Awad AG, Voruganti LNP. New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Can J Psychiatry. 2004; 49: 297-302.
4. Ayuso-Gutierrez JL, Del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997; 28: 199-206.
5. Azrin NH, Teichner G. Evaluation of an instructional program for improving medication compliance for chronically ill patients. Behav Res Ther. 1998; 36: 849-861.
6. Bartko G, Varadi H, Simon L et al. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int J Psychiatr Clin Pract 2002; 6: 9-14.
7. Brown CS, Wright RG, Christensen DB. Association between type of medication instruction and patient knowledge, side-effects and compliance. Hosp Comm Psychiatry. 1987; 38. 55-60.
8. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med. 1992; 22: 787-797.
9. Byerly MJ, Fisher R, Camody T et al. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005; 66: 997-1001.
10. Byerly M, Fischer R, Rush AJ et al. A comparison of clinician vs electronic monitoring of antipsychotic adherence in schizophrenia. ACNP Annual Meeting, San Juan, Puerto Rico 2002.
11. Cabeza TG, Amador MS, Lopez CA. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res. 2000; 41: 349-355.
12. Camfield CS, Chaplin A et al. Side effects of phenobarbital in toddlers. Behavioral and cognitive aspects. J Pediatr. 1979; 95: 361-365.
13. Claghorn J, Honigfeld G, Abuzzahab FS et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol. 1987; 7: 377-384.
14. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002; 106: 286-290.
15. Compton MT, Rudisch BE, Craw J, Thompson T, Owens DA. Predictors of missed first appointments at community mental health centers after psychiatric hospitalization. Psychiat Serv. 2006; 57: 531-537.
16. Compton MT. Treatment nonadherence among individuals with schizophrenia: Risk factors and strategies for improvement. Medscape 2006; www.medscape.com
17. Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clin Neuropharmacol. 1991; 14 (Suppl. 2): 324-330.
18. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998; 49: 196-201.
19. Cuffel BJ, Alford J, Fischer EP, Owen RR. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis. 1996; 184: 653-659.
20. Dencker SJ, Lieberman RP. From compliance to collaboration in the treatment of schizophrenia. Int Clin Psychopharmacol. 1995; 9 (Suppl. 5): 75-78.
21. Diaz E, Neuse E, Sullivan MS et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004; 65: 354-360.
22. Dixon L, Weiden P, Torres M et al. Assertive community treatment and medication compliance in the homeless mentally ill. Am J Psychiat. 1997; 154: 1302-1304.
23. Dolder CR, Lacro JP, Warren KA, Goldsham S, Perkins DO, Jeste DV. Brief evaluation of medication influences and beliefs. Development and testing of a Brief Scale for Medication Adherence. J Clin Psychopharmacol. 2004; 24: 404-409.
24. Dolder CR, Lacro JP, Jeste DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosomat Med. 2003; 65: 156-162.
25. Dolder CR, Lacro JP, Dunn LB et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002; 159: 103-108.
26. Donohoe G, Owens N, O'Donell C, Burke T, Moore L, Tobin A, O'Callaghan E. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiat. 2001; 16: 293-298.
27. Droulout T, Liraud F, Verdoux H. Relationship between insight and medication adherence in subjects with psychosis. Encephale 2003; 29: 430-437.
28. Eckman TA, Liberman RP, Phipps CC. Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol. 1990; 10: 33-38.
29. Fawcett J. Compliance: definitions and key issues. J Clin Psychiatry. 1995; 56 (Suppl. 1): 4-8.
30. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bull 1997; 23: 637-651.
31. Fleischhacker WW, Meise U, Gunther V et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiat Scand. 1994; 382 (Suppl.): 11-15.
32. Fletscher SW, Pappius EM, Harper SJ. Measurement of medication compliance in clinical setting. Comparison of three methods in patients prescribed digoxin. Arch Intern Med. 1979; 139: 635-638.
33. Gilmer TP, Odder CR, Lacro JP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004; 161: 692-699.
34. Gray R. Does patient education enhance compliance with clozapine? A preliminary investigation. J Psychiat Ment Health Nurs. 2000; 7: 285-286.
35. Hamann J, Cohen R, Leucht S et al. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiat. 2005; 162: 2382-2384.
36. Hayward P, Chan N, Kemp R et al. Medication self-management: a preliminary report of an intervention to improve medication compliance. J Ment Health. 1995; 4: 511-517.
37. Hellewell JS, Kalali AH, Langham SJ et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract. 1999; 3:105-113.
38. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003; 12: 423-424.
39. Hogan TP, Award AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983; 13: 177-183.
40. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a reexamination comparing two measures. Psychol Med. 1992; 22: 347-352.
41. Hudson TJ, Owen RR, Thrush CR et al. A pilot study to barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004; 65: 211-216.
42. Hummer M, Fleischhacker WW. Non-motor side effects of novel antipsychotics. Curr Opin CNS Invest Drugs. 2000; 2: 45-51.
43. Jasevic-Gasic M, Maric N, Damjanovic A. Risperidone liquid in psychotic disorders-efficacy and attitudes. Psychiatria Danubina. 2005; 17: 191-196.
44. Jay S, DuRaut RH, Litt IF et al. Riboflavin, self-report, and serum norethidrone. Am J Dis Child. 1984; 138: 70-73.
45. Johnson DAW, Pasterski JM, Ludlow JM et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983; 67: 339-352.
46. Jones IH. Riboflavin as an indicator of drug-taking behavior. Med J Austr 1967; 1: 202-204.
47. Kamali M, Kelly BD, Clarke M, Browne S, Gerrin M, Kinsella A, Lane A, Larkin C, O'Callaghan E. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry. 2006; 21: 29-33.
48. Kampman O, Lehtinen K, Lassila V, Leinonen E, Poutanen O, Koivista AM. Attitudes towards neuroleptic treatment: Reliability and validity of the Attitudes towards Neuroleptic Treatment (ANT) questionnaire. Schizophr Res. 2000; 45: 223-234.
49. Kane JM. What can we achieve by implementing a compliance-improvement program? Int Clin Psychopharmacol. 1997; 12 (Suppl. 1): 43-46.
50. Keith SJ, Kane JM. Partial compliance in schizophrenia: own patients can do better. J Clin Psychiatry. 2003; 64:1308-1315.
51. Kelly GR, Scott JE. Medication compliance and health education among outpatients with chronic mental disorders. Med Care. 1990; 28: 1181-1197.
52. Kemp R. Innovative approaches to improving compliance with antipsychotic treatment. Clear Perspectives: Management issues in schizophrenia: Patient satisfaction, compliance, and outcomes in schizophrenia. 1999; 2: 28-31.
53. Kemp R, Kirov G, Everitt B et al. Randomized controlled trial of compliance therapy: eighteen-month follow-up. Br J Psychiatry. 1998; 172: 413-419.
54. Kemp R, Hayward P. Applewhaite G et al. Compliance therapy in psychotic patients: randomized controlled trial. BMJ. 1996; 312: 345-349.
55. Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill noncompliant patients with schizophrenia. Int J Neuropsychopharmacol. 2003; 6: 97-102.
56. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. BMJ. 2004; 184: 509-516.
57. Kruse GR, Rohland BM. Factors associated with attendence at a first appointment after discharge from a psychiatric hospital. Psychiatr Serv. 2002a; 53: 473-476.
58. Kruse GR, Rohland BM, Wu X. Factors associated with missed first appointments at a psychiatric clinic. Psychiatr Serv. 2002b; 53: 1173-1176.
59. Kruse W, Weber E. Dynamics of drug regimen compliance - its assessment by microprocessor-based monitoring. Eur J Pharmacol. 1990; 38: 561-565.
60. Lam Y, Velligan D, Ereshefsky L et al. Intra-individual variability in plasma concentration as an indicator of adherence in schizophrenia. 42nd Annual Meeting, NCDEU, Boca Raton, June 10-13, 2002.
61. Lambert N, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psych Scand. 2005; 112: 141-148.
62. Lambert M, Conus P, Fide P, Mass R, Karow A, Moritz S, Golks D, Naber D. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiat. 2004; 19: 415-422.
63. Lacro JP, Dunn LB, Dolder CR et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63: 892-909.
64. Lecompte D, Pelc I. A cognitive-behavioral programme to improve compliance with medication in patients with schizophrenia. Int J Ment Health. 1996; 25: 51-56.
65. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006; 67 (Suppl. 5): 3-8.
66. Macharia WM, Leon G, Rowe BM, Stephenson BJ, Haynes RB. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA. 1992; 267: 1813-1817.
67. Macpherson R, Jerrom B, Hughes A. A controlled study of education about drug treatment in schizophrenia. Br J Psychiat. 1996; 168: 709-717.
68. Marder SROV. Overview of partial compliance. J Clin Psychiatry. 2003; 64 (Suppl. 16): 3-9.
69. McFvoy JP, Freter S, Everett G et al. Insight and the clinical outcome of schizophrenic patients. J Nerv Ment Dis. 1989; 177: 48-51.
70. Menzin J, Banlanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiat Serv. 2003; 54: 719-723.
71. Mojtabai R, Lavelle J, Gibson PJ et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv. 2002; 53: 337-339.
72. Mutsatsa SH, Loyce EM, Hutton SB et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003; 108: 439-446.
73. Naber O, Walther A, Kirchere T et al. Subjective effects of neuroleptics predict compliance. In: Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods. Eds. Gaebel W, Awad AG. Springer-Verlag, Heidelberg 1994; 111-122.
74. Nakonezny PA, Byerly MJ. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: A comparison of first- vs. second-generation antipsychotics. Schizophr Res. 2006; 82: 107-114.
75. Nelson EA, Marnish ME, Axler JL. Effects of discharge planning and compliance with outpatients appointments on readmission rate. Psychiatr Serv. 2000; 51: 885-889.
76. Nosé M, Barbui C, Gray R, Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Brit J Psychiat. 2003; 183: 197-206.
77. Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med. 2003; 33: 1149-1160.
78. Novick D. Antipsychotic treatment discontinuation in the outpatient treatment for schizophrenia: 24-month results from the Pan-European SOHO (Schizophrenia Outpatient Health Outcomes) study (Abstract). Biol Psychiatry. 2005; 57 (Suppl.): 715.
79. Novak-Grubic V, Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniphorm and schizoaffective disorder. Eur Psychiatry. 2002; 17: 148-154.
80. O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, Kinsella A, Larkin C, O'Callaghan E. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ. 2003; 327: 834-836.
81. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiat Scand. 2000; 102 (Suppl.): 83-86.
82. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiat Serv. 2000; 51: 216-222.
83. Patel NC, Crismon ML, Miller AL et al. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy. 2005; 25: 1242-1247.
84. Patterson T, Lacro J, McKibbin CL, Moscona S, Hughs T, Jeste DV. Medication Management Ability Assessment: Results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol. 2002; 22: 11-19.
85. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database. 2002; 2: C0002831.
86. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrino F, Green AI, Glick I, Kahn RS, Sharmal T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA, and HDDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006; 83: 53-63.
87. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002; 63: 1121-1128.
88. Pfeifer W, Kockott G, Fischl B et al. Unerwünschte Wirkungen psychopharmakologischer Langzeittherapie auf die sexuellen Funktionen. Psychiatr Prax. 1991; 18: 92-98.
89. Pitschel-Walz G, Bäuml J, Bender W, Engel RR, Wagner M, Kissling W. Psychoeducation and compliance in the treatment of schizophrenia: Results of the Munich Psychosis Information Project Study. J Clin Psychiatry. 2006; 67: 443-452.
90. Pitschel-Walz G, Leucht S, Baum J et al. The effect of family interventions on relapse and rehospitalizations in schizophrenia: a meta-analysis. Schizophr Bull. 2001; 27: 73-92.
91. Porter AMW. Drug defaulting in a general practice. Brit Med. J 1969; 1: 218-222.
92. Rabinowitz J, Bromet EJ, Davidson M. Comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. Schizophr Bull. 2001; 27: 597-600.
93. Rittmannsberger H, Pachinger T, Keppelmmeller P, Wancata J. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiat Serv. 2004; 55: 174-179.
94. Robinson D, Woerner MG, Alvir JMJ et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56: 241-247.
95. Rosenheck R, Chang S, Choe Y et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry. 2000; 61: 382-386.
96. Rummet CB, Hansen W-P, Helbig A et al. Peer-to-peer psychoeducation in schizophrenia: a new approach. J Clin Psychiatry. 2005; 66: 1580-1585.
97. Seltzer A, Roncar I, Garfinkel P. Effect of patient education on medication compliance. Can J Psychiat. 1980; 25: 638-645.
98. Sleator EK. Measurement of compliance. Psychopharm Bull. 1985; 21: 1089-1093.
99. Smith J, Birchwood M, Haddrell A. Informing people with schizophrenia about their illness: The effect of residual symptoms. J Ment Health. 1992; 1: 61-70.
100. Stricker SK, Amdur M, Dincin J. Educating patients about psychiatric medication: failure to enhance compliance. Psychosoc Rehabilitation. 1986; 4: 15-28.
101. Tattan MG, Creed FH. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull. 2001; 27: 149-155.
102. Thieda P, Beard S, Richter A et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003; 54: 508-516.
103. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000; 42: 241-247.
104. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004; 30: 255-264.
105. Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry. 1984; 41: 1036-1039.
106. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry. 1978; 35: 477-480.
107. Van Putten T. Why do schizophrenic patients refuse to take their medications? Arch Gen Psychiatr. 1974; 31: 67-72.
108. Voruganti LNR, Cortese L, Oyewumi L et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002; 57: 201-208.
109. Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjectives aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002; 56: 37-46.
110. Ward A, Ishak K, Proskorovsky I, Lam A, Caro J. Compliance with atypical antipsychotic agents, and hospitalization rates amongs patients with schizophrenia in Quebec (Abstract). Int J Neuropsychopharmacol. 2006; 9 (Suppl. 1): 266.
111. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiat Serv. 2004; 55: 886-891.
112. Weiden PJ, Mackell JA, Mc Donnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004; 66: 51-57.
113. Weiden P, Zygmunt A. Medication noncompliance in schizophrenia: I. Assessment. J Pract Psychiatry Behav Health. 1997; 3: 106-110.
114. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995; 21: 419-429.
115. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994; 20: 297-310.
116. Weiss K, Smith T, Hull J, Piper AC, Huppert JD. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychiatric disorders. Schizophr Bull. 2002; 28: 341-349.
117. Wright EC. Noncompliance or how many aunts has Mathilda? Lancet. 1993; 342: 909-913.
118. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiat. 2002; 159: 1653-1664.